Main idea: Preliminary data suggest that fecal microbiota transplantation is a potentially safe, well-tolerated, and efficacious treatment for certain conditions other than Clostridium difficile Infection, with evidence for active ulcerative colitis being the most compelling.
The intestinal microbiome has been identified as a key modifier for a variety of health conditions. Fecal Microbiota Transplantation has emerged as a fast, safe, and effective means by which to modify the intestinal microbiome and potentially treat a variety of health conditions. Serious adverse events were more often reported in control group participants compared with fecal microbiota transplantation group participants. Hepatic disorders, metabolic syndrome, and antibiotic-resistant organisms were conditions with emerging data on fecal bacteria transplantation. There were similar rates of mild to moderate comorbidities in both groups.